<DOC>
	<DOC>NCT00912964</DOC>
	<brief_summary>The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.</brief_summary>
	<brief_title>A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patient is willing and able to complete the micturition diary and questionnaires correctly Patient has symptoms of overactive bladder (OAB) for ≥ 3 months Patient must experience frequency of micturition on average ≥ 8 times per 24hour period during the 3day micturition diary period Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence during the 3day micturition diary period Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor Patient is using medications intended to treat OAB Patient has an indwelling catheter or practices intermittent selfcatheterization Patient has diabetic neuropathy Patient has evidence of urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs Patient receives nondrug treatment including electrostimulation therapy Patient has severe hypertension Patient has participated in a clinical study within 30 days, or had participated in any previous study with mirabegron Patient had an average total daily urine volume &gt; 3000 mL as recorded in the 3day micturition diary period Patient has serum creatinine of &gt;150 μmol/L, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2x upper limit of normal range (ULN), or gammaglutamyl transpeptidase (γGT) &gt; 3x ULN Patient has a clinically significant abnormal electrocardiogram (ECG)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Frequency</keyword>
	<keyword>Micturition</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Urinary urgency incontinence</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>YM178</keyword>
</DOC>